Prasco Laboratories
Prasco Laboratories is a privately held U.S. authorized-generic pharmaceutical company that manufactures and distributes therapeutically equivalent versions of branded drugs on behalf of brand owners, primarily serving U.S. pharmacies and healthcare providers with products like the authorized generic of GSK's Flovent.
- Company typePrivate
- Founded2002
- HeadquartersMason, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Prasco Laboratories does
Prasco Laboratories is a privately held U.S. pharmaceutical company headquartered in Mason, Ohio, founded in 2002 and operating with 51–100 employees. The company specializes in the manufacture and distribution of authorized generic versions of branded prescription medications, operating under a model in which original brand owners license Prasco to produce therapeutically equivalent generics, typically after branded products are discontinued or as a lifecycle management tool. Its flagship commercial product is the authorized generic version of GSK's Flovent (albuterol sulfate metered dose inhaler), which Prasco has distributed in the United States since GSK discontinued its branded Flovent line at the start of 2024.
Prasco generates revenue through the sale of authorized generic pharmaceuticals to retail and institutional pharmacies, hospital networks, and healthcare providers, using existing pharmaceutical distribution channels. Its go-to-market is partnership-driven rather than direct-to-consumer: the company secures licensing arrangements with brand owners such as GSK, then routes product through established U.S. pharmacy wholesalers and provider networks. In December 2025, Prasco announced a strategic collaboration with Frontier Scientific Solutions to add temperature-controlled logistics capabilities, aimed at reducing damages, theft, and shortages as the portfolio expands.
The business carries structural concentration risk: revenue appears heavily tied to the GSK/Flovent authorized-generic franchise, and the 2024 FDA approval of Glenmark's true generic version of Flovent with 180-day market exclusivity directly threatens authorized-generic economics going forward. Leadership is family-controlled, with E. Thomas Arington as founder and chairman and Christopher Arington as vice chairman and CEO. The company does not disclose revenue, has not raised institutional funding, and operates exclusively in the U.S. market with no public listing.
Prasco Laboratories firmographics
Firmographics- Name
- Prasco Laboratories
- Legal name
- Prasco Laboratories
- Website
- https://prasco.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Prasco Laboratories is a privately held U.S. authorized-generic pharmaceutical company that manufactures and distributes therapeutically equivalent versions of branded drugs on behalf of brand owners, primarily serving U.S. pharmacies and healthcare providers with products like the authorized generic of GSK's Flovent.
- Ownership category
- akta.pro rank
Prasco Laboratories industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)
- akta.pro secondary industries
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Specialty Pharmaceutical Distributors (HLAIAJAB)
Keywords
Where Prasco Laboratories is headquartered
LocationHeadquarters
- HQ city
- Mason
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Prasco Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Authorized Generic Pharmaceutical Manufacturing: Prasco manufactures and distributes authorized generic versions of branded pharmaceutical products through partnerships with original drug manufacturers like GSK. Revenue is generated through the sale of these generics to pharmacies and healthcare providers, with pricing typically lower than branded equivalents while maintaining therapeutic equivalence.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels1 record
Prasco Laboratories product offering
Product offeringCore offering
Prasco Laboratories manufactures and distributes authorized generic versions of branded pharmaceutical products, operating as a partner to originator drug manufacturers. Its flagship offering is the authorized generic of GSK's Flovent (fluticasone propionate) asthma inhaler, produced under partnership agreements and sold through U.S. pharmacy distribution channels. The company specializes in providing therapeutic equivalents at lower price points while maintaining FDA-compliant manufacturing standards.
Product overview
Prasco Laboratories operates as an authorized generic pharmaceutical company, distributing generic versions of branded medications through partnerships with original manufacturers. The company's primary product offering is the authorized generic version of GSK's Flovent asthma inhaler, which they distribute through their partnership with GSK. They do not appear to offer a unified platform but rather serve as a distribution channel for manufacturer-authorized generic pharmaceuticals.
Differentiator
Problem solved
Functional benefit
Products and services
- Authorized Generic Flovent Authorized generic versions of GSK's Flovent (fluticasone propionate) asthma inhaler, manufactured and distributed by Prasco under partnership with GSK following discontinuation of the branded product. Marketed to retail and institutional pharmacies and dispensed to patients with chronic respiratory conditions such as asthma.
Quantifiable outcome
- Expansion of patient access to affordable asthma treatment through authorized generic distribution
Companies that use Prasco Laboratories
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Prasco Laboratories technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Prasco Laboratories partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and flagship.
- Frontier Scientific SolutionscorePrasco Laboratories announced a strategic collaboration with Frontier Scientific Solutions to enhance pharmaceutical supply chain logistics. The partnership leverages Frontier's temperature-controlled logistics capabilities to address industry challenges including damages, theft, and shortages. The alliance aims to ensure product integrity and safety, reflecting the growing importance of specialized logistics in the expanding pharmaceutical market.
- GSKflagshipGSK partnered with Prasco Laboratories as an authorized generic partner for its Flovent asthma inhaler products. GSK discontinued its branded versions of Flovent at the start of 2024 and has since sold authorized generic versions through its Ohio-based partner Prasco Laboratories. This partnership allowed GSK to manage market transitions while maintaining patient access to the medication through lower-cost generic alternatives.
Scale indicators1 record
Recent moves5 records
Expansion highlights3 records
Prasco Laboratories competitors and assessment
Company assessmentBroad incumbents
- Sandoz: Global generic and biosimilar leader that maintains authorized-generic and private-label arrangements with originator companies, overlapping with Prasco's authorized-generic business model. Operates at meaningfully greater scale across therapeutic areas.
- Viatris (Mylan): Large generic pharmaceutical manufacturer with broad respiratory portfolio including generic Advair Diskus and other authorized and traditional generic offerings that overlap with Prasco's therapeutic-area focus and authorized-generic distribution model.
- Teva Pharmaceutical Industries: One of the largest generic pharmaceutical manufacturers globally with significant respiratory franchise (including generic ProAir and Proventil HFA inhalers). Competes with Prasco in respiratory generic inhalers and authorized-generic-type arrangements.
- Mallinckrodt Pharmaceuticals: Specialty/generic pharmaceutical manufacturer with respiratory, allergy, and specialty brands plus generics portfolio, partially overlapping with Prasco's authorized-generic distribution focus in respiratory and specialty therapeutic areas.
- Hikma Pharmaceuticals: Generic and specialty pharmaceutical manufacturer with US respiratory franchise (including generic albuterol sulfate). Operates comparable authorized-generic and traditional generic inhalation-product business serving US healthcare providers.
Direct peers
- Apotex: Canadian-headquartered generic pharmaceutical manufacturer with US distribution and authorized-generic arrangements. Comparable business model as a multi-therapeutic authorized-generic and traditional generic manufacturer serving US pharmacy and institutional channels.
- Glenmark Pharmaceuticals: Direct competitor in the US generic respiratory market. Glenmark received FDA approval for the first true generic version of GSK's Flovent, directly challenging Prasco's authorized generic of the same molecule for the same patient population.
- Amneal Pharmaceuticals: US-focused generic pharmaceutical manufacturer with respiratory franchise (e.g., generic albuterol sulfate inhalation aerosol). Operates similar authorized-generic and traditional generic manufacturing/distribution model targeting overlapping pharmacy channels.
- Lupin Pharmaceuticals: Generic pharmaceutical manufacturer with US respiratory portfolio (including generic albuterol HFA). Competes with Prasco in the same therapeutic category using a similar generic manufacturing and US distribution model to pharmacy customers.
Others
- Organon & Co. Women's health and established brands company that has pursued authorized-generic strategies for lifecycle management of legacy branded assets. Operates in adjacent brand-lifecycle dynamics that drive demand for authorized-generic partners like Prasco.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Prasco Laboratories social profiles
Digital presencePrasco Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prasco Laboratories leadership team
Management profileNumber of profiles
Profiles2 records
Prasco Laboratories funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prasco Laboratories M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prasco Laboratories
What does Prasco Laboratories do?
Prasco Laboratories manufactures and distributes authorized generic versions of branded pharmaceutical products, operating as a partner to originator drug manufacturers. Its flagship offering is the authorized generic of GSK's Flovent (fluticasone propionate) asthma inhaler, produced under partnership agreements and sold through U.S. pharmacy distribution channels. The company specializes in providing therapeutic equivalents at lower price points while maintaining FDA-compliant manufacturing standards.
Is Prasco Laboratories a public or private company?
Prasco Laboratories is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Prasco Laboratories founded?
Prasco Laboratories was founded in 2002. It employs 51 to 100 people.
Where is Prasco Laboratories based?
Prasco Laboratories is headquartered in Mason, United States, in the North America region.
How does Prasco Laboratories make money?
One revenue line is on record: authorized Generic Pharmaceutical Manufacturing.
Who are Prasco Laboratories's main competitors?
Broad incumbents on record are Sandoz, Viatris (Mylan), Teva Pharmaceutical Industries, Mallinckrodt Pharmaceuticals and Hikma Pharmaceuticals. Direct peers are Apotex, Glenmark Pharmaceuticals, Amneal Pharmaceuticals and Lupin Pharmaceuticals. Organon & Co. is listed as an others.
Does Prasco Laboratories have an API?
No public API is recorded for Prasco Laboratories.
What industry is Prasco Laboratories in?
Prasco Laboratories's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions, with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.